Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
BHC Stock Forecast 2025-2026
$6.42
Current Price
$2.38B
Market Cap
Buy 1
Hold 5
Sell 1
Wall St Analyst Ratings
Distance to BHC Price Targets
+55.8%
To High Target of $10.00
+9.0%
To Median Target of $7.00
-22.1%
To Low Target of $5.00
BHC Price Momentum
-9.1%
1 Week Change
+7.4%
1 Month Change
-13.5%
1 Year Change
-20.3%
Year-to-Date Change
-34.8%
From 52W High of $9.85
+62.1%
From 52W Low of $3.96
📊 TOP ANALYST CALLS
Did BHC Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Bausch Health is one of their latest high-conviction picks.
Latest BHC Stock Price Targets & Analyst Predictions
Based on our analysis of 14 Wall Street analysts, BHC has a neutral consensus with a median price target of $7.00 (ranging from $5.00 to $10.00). Currently trading at $6.42, the median forecast implies a 9.0% upside. This outlook is supported by 1 Buy, 5 Hold, and 1 Sell ratings.
The most optimistic forecast comes from Douglas Miehm at RBC Capital, projecting a 55.8% upside. Conversely, the most conservative target is provided by Douglas Miehm at RBC Capital, suggesting a 22.1% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
BHC Analyst Ratings
1
Buy
5
Hold
1
Sell
BHC Price Target Range
Low
$5.00
Average
$7.00
High
$10.00
Current: $6.42
Latest BHC Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for BHC.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 2, 2025 | RBC Capital | Douglas Miehm | Sector Perform | Maintains | $10.00 |
| Feb 6, 2025 | Jefferies | David Steinberg | Hold | Downgrade | $8.00 |
| Jan 30, 2025 | RBC Capital | Douglas Miehm | Sector Perform | Maintains | $10.00 |
| Nov 1, 2024 | RBC Capital | Douglas Miehm | Sector Perform | Maintains | $11.00 |
| Aug 2, 2024 | Piper Sandler | David Amsellem | Underweight | Downgrade | $3.00 |
| Aug 2, 2024 | RBC Capital | Douglas Miehm | Sector Perform | Maintains | $8.50 |
| Jul 25, 2024 | Truist Securities | Gregory Fraser | Hold | Maintains | $7.00 |
| Jul 10, 2024 | Raymond James | Michael Freeman | Market Perform | Initiates | $8.00 |
| Apr 23, 2024 | RBC Capital | Douglas Miehm | Sector Perform | Maintains | $11.00 |
| Apr 12, 2024 | RBC Capital | Douglas Miehm | Sector Perform | Reiterates | $12.00 |
| Apr 5, 2024 | RBC Capital | Douglas Miehm | Sector Perform | Maintains | $12.00 |
| Feb 23, 2024 | RBC Capital | Douglas Miehm | Sector Perform | Maintains | $9.00 |
| Sep 20, 2023 | Jefferies | David Steinberg | Buy | Upgrade | $16.00 |
| Jun 16, 2023 | TD Cowen | Ken Cacciatore | Market Perform | Downgrade | $0.00 |
| May 22, 2023 | Jefferies | David Steinberg | Buy | Maintains | $9.50 |
| May 5, 2023 | RBC Capital | Douglas Miehm | Sector Perform | Maintains | $8.00 |
| Sep 9, 2022 | Piper Sandler | David Amsellem | Neutral | Maintains | $6.00 |
| Sep 1, 2022 | RBC Capital | Douglas Miehm | Sector Perform | Maintains | $8.00 |
| Aug 10, 2022 | RBC Capital | Douglas Miehm | Sector Perform | Maintains | $4.50 |
| Aug 10, 2022 | BMO Capital | Gary Nachman | Market Perform | Maintains | $8.00 |
Bausch Health Companies Inc. (BHC) Competitors
The following stocks are similar to Bausch Health based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Bausch Health Companies Inc. (BHC) Financial Data
Bausch Health Companies Inc. has a market capitalization of $2.38B with a P/E ratio of -49.4x. The company generates $9.73B in trailing twelve-month revenue with a -0.4% profit margin.
Revenue growth is +4.9% quarter-over-quarter, while maintaining an operating margin of +11.9% and return on equity of +14.3%.
Valuation Metrics
Market Cap
$2.38B
Enterprise Value
$23.78B
P/E Ratio
-49.4x
PEG Ratio
1.5x
Price/Sales
0.2x
Growth & Margins
Revenue Growth (YoY)
+4.9%
Gross Margin
+69.0%
Operating Margin
+11.9%
Net Margin
-0.4%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+47.8%
Current Ratio
1.3x
Debt/Equity
-89.6x
ROE
+14.3%
ROA
+4.3%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Bausch Health Companies Inc. (BHC) Business Model
About Bausch Health Companies Inc.
What They Do
Global pharmaceutical and medical device enterprise.
Business Model
The company generates revenue by offering a diverse range of medical solutions, including prescription pharmaceuticals, over-the-counter products, and medical devices, primarily in ophthalmology, gastroenterology, and dermatology. By serving both patients and healthcare professionals, Bausch Health aims to address various medical needs, thus creating multiple revenue streams within the healthcare market.
Additional Information
Bausch Health is headquartered in Laval, Canada, and is recognized for its extensive portfolio of therapies and products. The company emphasizes innovation through continual investments in research and development, aiming to improve patient care and health outcomes globally.
Company Information
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
20,700
CEO
Mr. Thomas J. Appio
Country
Canada
IPO Year
2018
Website
www.bauschhealth.comBausch Health Companies Inc. (BHC) Latest News & Analysis
Latest News
Quick Summary
Bausch Health Companies appointed Steven Lee as Senior Vice President, Controller, and Chief Accounting Officer, effective July 14, 2025. He has a strong background in financial transformation and M&A.
Why It Matters
The appointment of Steven Lee, with expertise in financial transformation and M&A, suggests a strategic focus on improving Bausch Health's financial performance and growth potential, impacting investor confidence.
Source: Accesswire
Market Sentiment:
Neutral
Quick Summary
Bausch Health announced that its acne treatment, PrCABTREOTM, is now available in Ontario, Nova Scotia, and through federal drug plans for Indigenous populations and correctional facilities.
Why It Matters
The availability of CABTREO in public drug plans expands Bausch Health's market reach, potentially boosting sales and improving revenue outlook, which could positively impact stock performance.
Source: Accesswire
Market Sentiment:
Neutral
Quick Summary
Bausch Health's Salix Pharmaceuticals launched the "I Wish I Knew" campaign for Xifaxan, aimed at raising awareness about hepatic encephalopathy and educating patients on managing their liver disease.
Why It Matters
Bausch Health's DTC campaign for Xifaxan may boost sales by increasing awareness and patient engagement in treating hepatic encephalopathy, positively impacting revenue and market perception.
Source: Accesswire
Market Sentiment:
Neutral
Quick Summary
Bausch Health's PrCABTREOTM gel for acne is now available through public drug plans in Ontario and Nova Scotia, and federal plans for Indigenous populations and correctional services.
Why It Matters
Bausch Health's new acne treatment gaining public drug plan coverage can boost sales and market share, potentially improving revenue and stock performance for the company.
Source: Accesswire
Market Sentiment:
Neutral
Quick Summary
Bausch Health Companies Inc. (NYSE:BHC) will release Q2 2025 financial results on July 30, 2025, after market close, followed by a conference call at 5:00 p.m.
Why It Matters
Bausch Health's upcoming Q2 2025 financial results and conference call may influence stock performance and investor sentiment, impacting trading decisions and market perceptions.
Source: Accesswire
Market Sentiment:
Neutral
Quick Summary
Bausch + Lomb has closed an upsized offering of €675 million in senior secured floating rate notes due 2031, enhancing its financial position.
Why It Matters
Bausch + Lomb's €675 million bond offering indicates strong demand for its debt, enhancing liquidity and financial stability, which can boost investor confidence and impact stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Frequently Asked Questions About BHC Stock
What is Bausch Health Companies Inc.'s (BHC) stock forecast for 2026?
Based on our analysis of 14 Wall Street analysts, Bausch Health Companies Inc. (BHC) has a median price target of $7.00. The highest price target is $10.00 and the lowest is $5.00.
Is BHC stock a good investment in 2026?
According to current analyst ratings, BHC has 1 Buy ratings, 5 Hold ratings, and 1 Sell ratings. The stock is currently trading at $6.42. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for BHC stock?
Wall Street analysts predict BHC stock could reach $7.00 in the next 12 months. This represents a 9.0% increase from the current price of $6.42. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Bausch Health Companies Inc.'s business model?
The company generates revenue by offering a diverse range of medical solutions, including prescription pharmaceuticals, over-the-counter products, and medical devices, primarily in ophthalmology, gastroenterology, and dermatology. By serving both patients and healthcare professionals, Bausch Health aims to address various medical needs, thus creating multiple revenue streams within the healthcare market.
What is the highest forecasted price for BHC Bausch Health Companies Inc.?
The highest price target for BHC is $10.00 from Douglas Miehm at RBC Capital, which represents a 55.8% increase from the current price of $6.42.
What is the lowest forecasted price for BHC Bausch Health Companies Inc.?
The lowest price target for BHC is $5.00 from Douglas Miehm at RBC Capital, which represents a -22.1% decrease from the current price of $6.42.
What is the overall BHC consensus from analysts for Bausch Health Companies Inc.?
The overall analyst consensus for BHC is neutral. Out of 14 Wall Street analysts, 1 rate it as Buy, 5 as Hold, and 1 as Sell, with a median price target of $7.00.
How accurate are BHC stock price projections?
Stock price projections, including those for Bausch Health Companies Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 13, 2025 12:39 PM UTC